<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>175</id><JournalTitle>ADVERSE DRUG REACTIONS ASSOCIATED WITH HERBAL MEDICINES: A REVIEW</JournalTitle><Abstract>Adverse Drug Reactions Associated with Herbal Medicines represents a critical dimension of botanical medicine science
that bridges traditional plant-based medicine heritage with modern pharmaceutical standards for quality, safety, and
regulatory compliance [1, 2]. The global significance of herbal medicines—used by approximately 80% of the world's
population and representing a multi-billion dollar industry in high-income countries—underscores the public health
importance of rigorous adverse drug reactions associated with herbal medicines science [3, 4]. Key advances in adverse
drug reactions associated with herbal medicines include: application of ultra-high-performance liquid chromatography
coupled with high-resolution mass spectrometry (UHPLC-HRMS) metabolomics for comprehensive botanical profiling
and authentication; deployment of DNA barcoding for molecular species verification; implementation of WHO Good
Agricultural and Collection Practices (GACP) standards for botanical supply chain quality; and development of
pharmacovigilance frameworks specifically adapted for herbal medicine adverse event monitoring and causality
assessment [5, 6, 7]. Critical challenges in adverse drug reactions associated with herbal medicines include: botanical
identity verification and adulteration prevention; pyrrolizidine alkaloid and aristolochic acid contamination monitoring;
herb-drug interaction characterisation (particularly CYP3A4/P-gp-mediated interactions involving St. John's wort);
hepatotoxicity risk assessment for botanicals with hepatotoxic signal; heavy metal and pesticide contaminant control; and
international regulatory harmonisation enabling global market access for quality botanical products [8, 9, 10]. Regulatory
frameworks governing adverse drug reactions associated with herbal medicines have matured substantially: the FDA
Botanical Drug Guidance (2016/2023) and EU THMPD (2004/24/EC) with EMA HMPC community herbal monographs
provide the most comprehensive frameworks globally, supplemented by WHO traditional medicine strategy and
guidance documents [5, 6]. This review consolidates current knowledge on adverse drug reactions associated with herbal
medicines, examining scientific advances, regulatory developments, safety evidence, quality standards, and priorities for
future research and regulatory harmonisation</Abstract><Email>godsonrani12@gmail.com</Email><articletype>Research</articletype><volume>16</volume><issue>2</issue><year>2026</year><keyword>Adverse Drug Reactions; Herbal Medicines; Hepatotoxicity; Herb-Drug Interactions; Allergic Reactions; Cardiovascular Toxicity; Nephrotoxicity; Pharmacovigilance; Spontaneous Reporting</keyword><AUTHORS>Jansi Rani I</AUTHORS><afflication>Assistant Professor, Department of Pharmacognosy, St.Mary’s Institute of Pharmacy, Chinthamani, Puliankudi. - 627855</afflication></Article></Articles>